IOVA - Personalized Skin Cancer Therapy Despite FDA Delay: Analysts Show Confidence In Iovance Biotherapeutics Therapy | Benzinga
Thursday, the FDA extended the review period for Iovance Biotherapeutics Inc's (NASDAQ: IOVA) marketing application seeking accelerated approval for lifileucel for advanced melanoma.
The new target action date for a decision under the Prescription Drug User Fee Act is February 24, 2024, from November 25, 2023.
The FDA agreed to work with Iovance to expedite the remaining review for a potentially earlier approval date.
The ...